The Effect of Ranolazine on Left Ventricular Function After Myocardial Infarction

Investigating the effects of ranolazine on left ventricular function after acute myocardial infarction

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260126068670N1

Enrollment

180

Registered

2026-01-30

Start date

2026-01-21

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial ischemia patients.

Interventions

Intervention group:Ranolazine.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with MI referred to Bu Ali Hospital in Qazvin during 1404-1405 who underwent PPCI within the first 24 hours of pain Ages between 18 and 75 years old STEMI patients with ejection fraction (EF) = 40%

Exclusion criteria

Exclusion criteria: Incompleteness of individual files Patients with a history of prior MI within the past 30 days or CABG Severe and recurrent arrhythmia Patients who have previously undergone PCI or received thrombolytics End-stage lung or liver disease Severe valvular heart disease GFR 500 Cardiogenic shock Common drugs that cause changes in the QT interval

Design outcomes

Primary

Measure	Time frame
Determining the effects of ranolazine on left ventricular function 8 weeks after acute myocardial infarction. Timepoint: Study start and week 8. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Changes in left ventricular volumes. Timepoint: Study start and week 8. Method of measurement: Echocardiography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmajid haji karimi

Qazvin University of Medical Sciences

Medicine@qums.ac.ir+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026